Applications of positron-emitting halogens in PET oncology (Review)

Glaser, Matthias; Luthra, Sajinder K.; Brady, F.

doi:10.3892/ijo.22.2.253

Cited by 24 publications

(24 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of its nontumor uptake, 18 F-FLT might not be suitable to work alone or to replace 18 F-FDG in the diagnosis or differentiation of pulmonary lesions. One problem with 18 F-FLT was its fairly low production yield and success rate in synthesis (7,12). With the commercially available automatic synthesizer used in our trial, the production succeeded only two thirds of the time, with an average yield of around 13%.…”

Section: Comparison Of 18 F-flt and 18 F-fdgmentioning

confidence: 99%

A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3′-Deoxy-3′-¹⁸F-Fluorothymidine and ¹⁸F-FDG

Tian¹,

Yang²,

Yu³

et al. 2008

J Nucl Med

View full text Add to dashboard Cite

Some new radiotracers might add useful information and improve diagnostic confidence of 18 F-FDG imaging in tumors. A multicenter clinical trial was designed to investigate the diagnostic performance of dual-tracer ( 18 F-FDG and 39-deoxy-39-18 F-fluorothymidine [ 18 F-FLT]) PET/CT in pulmonary nodules. Methods: Fifty-five patients underwent dual-tracer imaging in 6 imaging centers using the same models of equipment and standardized protocols. The images were interpreted by a collective group of readers who were unaware of the clinical data. The diagnostic performance using either tracer alone or dual-tracers together, with or without CT, was compared. The histological diagnosis or clinical findings in a 12-mo follow-up period served as the standard of truth. Results: In 16 patients with malignant tumor, 16 with tuberculosis, and 23 with other benign lesions, the sensitivity and specificity of 18 F-FDG and 18 F-FLT were 87.5% and 58.97% and 68.75% and 76.92%, respectively. The combination of dual-tracer PET/CT improved the sensitivity and specificity up to 100% and 89.74%. The 3 subgroups of patients could be best separated when the 18 F-FLT/ 18 F-FDG standardized uptake value ratio of 0.4-0.90 was used as the threshold. Conclusion: By reflecting different biologic features, the dualtracer PET/CT using 18 F-FDG and 18 F-FLT favorably affected the diagnosis of lung nodules.

show abstract

Section: Comparison Of 18 F-flt and 18 F-fdgmentioning

confidence: 99%

A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3′-Deoxy-3′-¹⁸F-Fluorothymidine and ¹⁸F-FDG

Tian¹,

Yang²,

Yu³

et al. 2008

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…Because of the biologic half-life of L19-SIP, a positron-emitting radionuclide with a half-life longer than that of 18 (26)(27)(28)(29)(30)(31) because of its favorable halflife that allows imaging up to 48 h after injection, its high production yields (at least an order of magnitude higher than that of 124 I), and its 54% positron emission (;2-fold higher than that of 124 I) (32). For these reasons, and due to the well-established labeling chemistry, we have labeled L19-SIP with 76 Br.…”

mentioning

confidence: 99%

Small-Animal PET of Tumor Angiogenesis Using a 76Br-Labeled Human Recombinant Antibody Fragment to the ED-B Domain of Fibronectin

Rossin¹,

Berndorff²,

Friebe³

et al. 2007

Journal of Nuclear Medicine

View full text Add to dashboard Cite

The aim of this study was to image the extra domain B (ED-B) of fibronectin, an angiogenesis-related target, in solid tumors using small-animal PET. Toward this aim, an ED-B fibronectin-binding human antibody derivative (L19-SIP) was labeled with 76 Br via an enzymatic approach. Biodistribution and imaging studies were performed in human teratoma-bearing mice for up to 48 h after injection. Methods: L19-SIP was labeled with 76 Br using bromoperoxidase/H 2 O 2 . The stability of the labeled antibody was tested both in vitro and in vivo. Biodistribution and small-animal imaging studies (PET and CT) were performed in F9-bearing 129/ sv mice (n 5 3 or 4). Results: The enzymatic radiobromination approach afforded the labeled antibody in high yield (.55%) under mild reaction conditions. 76 Br-L19-SIP stability in mouse serum proved to be similar to that of the 125 I-labeled analog (.80% of intact material at 48 h after injection). Fast and specific in vivo targeting was obtained in tumors and other organs expressing ED-B fibronectin (i.e., ovaries and uterus). However, slow renal clearance and persistent activity predominately in blood and stomach suggests partial 76 Br-L19-SIP debromination in vivo. This debromination was confirmed in a metabolism study in normal mice. The F9 tumors were clearly imaged by small-animal PET at each considered time point, starting at 5 h up to 48 h after injection. Conclusion: 76 Br-L19-SIP specifically accumulated at the target site, enabling detailed small-animal PET of tumor neovasculature. Therefore, targeting the angiogenesis-associated expression of ED-B fibronectin can be a valuable tool for tumor detection using molecular imaging with PET.

show abstract

“…If patient is having tumor the radioactive substance gets accumulated in the tumor. The PET scanner captures the distribution of radioactive substance in the body [18][19]. The computer then translates the distribution of radioactive substance into an image which then is interpreted by a radiologist, to detect tumor given the fact that cancer cells absorb more radioactive substance than other tissues in the body.…”

Section: Positron Emission Tomography (Pet)mentioning

confidence: 99%

Imaging Techniques for Cancer Diagnosis and Scope for Enhancement

Malik¹,

Lone²,

Quadri³

2016

IJIGSP

View full text Add to dashboard Cite

Abstract-Imaging techniques are used to create images of structure, function and pathology of human body organs for cancer diagnosis. Various imaging techniques like X-ray, Positron Emission Tomography (PET), Ultrasound (US), MRI etc. are used for cancer diagnosis. These imaging techniques have gone through Lot of advancements during last few years. These techniques vary in the technology and application. Various artifacts exist in these imaging techniques and images produced by theses imaging techniques. These artifacts can be exploited to enhance the imaging technique and the images produced by them.

show abstract

Applications of positron-emitting halogens in PET oncology (Review)

Cited by 24 publications

References 85 publications

A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3′-Deoxy-3′-¹⁸F-Fluorothymidine and ¹⁸F-FDG

A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3′-Deoxy-3′-¹⁸F-Fluorothymidine and ¹⁸F-FDG

Small-Animal PET of Tumor Angiogenesis Using a 76Br-Labeled Human Recombinant Antibody Fragment to the ED-B Domain of Fibronectin

Imaging Techniques for Cancer Diagnosis and Scope for Enhancement

Contact Info

Product

Resources

About

Applications of positron-emitting halogens in PET oncology (Review)

Cited by 24 publications

References 85 publications

A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3′-Deoxy-3′-18F-Fluorothymidine and 18F-FDG

A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3′-Deoxy-3′-18F-Fluorothymidine and 18F-FDG

Small-Animal PET of Tumor Angiogenesis Using a 76Br-Labeled Human Recombinant Antibody Fragment to the ED-B Domain of Fibronectin

Imaging Techniques for Cancer Diagnosis and Scope for Enhancement

Contact Info

Product

Resources

About

A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3′-Deoxy-3′-¹⁸F-Fluorothymidine and ¹⁸F-FDG

A Multicenter Clinical Trial on the Diagnostic Value of Dual-Tracer PET/CT in Pulmonary Lesions Using 3′-Deoxy-3′-¹⁸F-Fluorothymidine and ¹⁸F-FDG